Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지

Imatinib Mesylate Versus Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic Myelogenous Leukemia

  • Zhang, Gui-Fang (Department of Hematology, First People's Hospital of Changshu) ;
  • Zhou, Min (Department of Hematology, First People's Hospital of Changshu) ;
  • Bao, Xie-Bing (Leukemia Research Division, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, First Affiliated Hospital of Soochow University) ;
  • Qiu, Hui-Ying (Leukemia Research Division, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, First Affiliated Hospital of Soochow University) ;
  • Li, Zheng (Leukemia Research Division, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, First Affiliated Hospital of Soochow University) ;
  • Xue, Sheng-Li (Leukemia Research Division, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, First Affiliated Hospital of Soochow University)
  • Published : 2016.09.01
⟨ Previous Next ⟩

Abstract

Purpose: To compare the relative merits of imatinib and allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myelogenous leukemia (CML). Materials and Methods: This cohort study was designed to compare the outcomes of imatinib (n=292) versus allo-HSCT (n=141) for CML, the clinical data of these patients being retrospectively analyzed so as to compare the event free survival (EFS) and overall survival (OS) between these two groups with patients in the chronic phase (CP) and advanced phases, including accelerate (AP) and blast phases (BP). Results: (1) Patients treated with imatinib (278 in the CP) demonstrated superior EFS, OS, 5-year EFS and 5-year OS rates of 88.5% versus 70.0% (P<0.05), 93.2% versus 80.0% (P<0.05), 84% versus 75.0% (P<0.05) and 92% versus 79.0% (P<0.05), respectively, to those treated with allo-HSCT (120 patients in the CP). (2) Both treatments resulted in similar survival, with EFS and OS rates of 42.9% versus 47.6% (P>0.05), 42.9% versus 57.1% (P> 0.05), respectively, for imatinib (14 patients in the AP and BP) and allo-HSCT (21 patients in the AP and BP). Conclusions: Imatinib confers significant survival advantage (EFS and OS) for CML patients with CP compared with allo-HSCT treatment. However, the outcomes are equally good with both treatments in AP and BP patients.

Keywords

Acknowledgement

Supported by : National Natural Scientific Foundation

References

  1. Baccarani M, Saglio G, Goldman J, et al (2006). Evolving concepts in the management of chronic myeloid leukemia, recommendations from an expert panel on behalf of the European LeukemiaNe. Blood, 108, 1809-20. https://doi.org/10.1182/blood-2006-02-005686
  2. Barrett AJ, Ito S (2015). The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. Blood, 125, 3230-5. https://doi.org/10.1182/blood-2014-10-567784
  3. Castagnetti F, Gugliotta G, Breccia M, et al (2015). Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia, 29, 1823-31. https://doi.org/10.1038/leu.2015.152
  4. Cortes J, Jabbour E, Kantarjian H, et al (2007). Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood, 110, 4005-11. https://doi.org/10.1182/blood-2007-03-080838
  5. Firwana B, Sonbol MB, Diab M, et al (2016). Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia inchronic phase, A mixed-treatment comparison. Int J Cancer, 138, 1545-53. https://doi.org/10.1002/ijc.29889
  6. Goldman JM, Melo JF (2003). Chronic myeloid leukemia advances in biology and new approaches to treatment. N Engl J Med, 349, 1461-64.
  7. Gratwohl A, Brand R, Apperley J, et al (2006). Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006, transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica, 91, 513-21.
  8. Gratwohl A, Heim D (2009). Current role of stem cell transplantation in chronic myeloid leukaemia. Best Pract Res Clin Haematol, 22, 431-43. https://doi.org/10.1016/j.beha.2009.05.002
  9. Hehlmann R, Berger U, Pfirrmann M, et al (2007). Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood, 109, 4686-92. https://doi.org/10.1182/blood-2006-11-055186
  10. Hochhaus A, O'Brien SG, Guilhot F, et al (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 23, 1054-61. https://doi.org/10.1038/leu.2009.38
  11. Jabbour E (2016). Chronic myeloid leukemia, First-line drug of choice. Am J Hematol, 91, 59-66. https://doi.org/10.1002/ajh.24249
  12. Jabbour E, Kantarjian H, Jones D, et al (2008). Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood, 112, 53-5. https://doi.org/10.1182/blood-2007-11-123950
  13. Jiang Q, Xu LP, Liu DH, et al (2011). Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood, 117, 3032-40. https://doi.org/10.1182/blood-2010-09-308510
  14. Jiang Q, Zhao D, Jin J, et al (2015). A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia. Zhonghua Xue Ye Xue Za Zhi, 36, 651-5.
  15. Kujak C, Kolesar JM (2016). Treatment of chronic myelogenous leukemia. Am J Health Syst Pharm, 73, 113-20. https://doi.org/10.2146/ajhp140686
  16. Moslehi JJ, Deininger M (2015). Tyrosine kinase inhibitorassociated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol, 33, 4210-8. https://doi.org/10.1200/JCO.2015.62.4718
  17. Nair AP, Barnett MJ, Broady RC, et al (2015). Allogeneic hematopoietic stem cell transplantation is an effective salvage therapy for patients with chronicmyeloid leukemia presenting with advanced disease or failing treatment with tyrosine kinase inhibitors. Biol Blood Marrow Transplant, 21, 1437-44. https://doi.org/10.1016/j.bbmt.2015.04.005
  18. O'Brien S, Radich JP, Abboud CN, et al (2014).Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw, 12, 1590-610. https://doi.org/10.6004/jnccn.2014.0159
  19. Pagnano KB, Bendit I, Boquimpani C, et al (2015). BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival. Cancer Invest, 33, 451-8. https://doi.org/10.3109/07357907.2015.1065499
  20. Ruiz-Cordell K, Haimowitz S, Gracie-King L, et al (2016). Optimizing the use of TKIs in the management of chronic myelogenous leukemia. Clin Lymphoma Myeloma Leuk, 16, 442-6. https://doi.org/10.1016/j.clml.2016.04.005
  21. Sasaki K, Kantarjian HM, Jain P, et al (2016). Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer, 122, 238-48. https://doi.org/10.1002/cncr.29745
  22. Saussele S, Lauseker M, Gratwohl A, et al (2010). Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era, evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 115, 1880-5. https://doi.org/10.1182/blood-2009-08-237115
  23. Schiffer CA (2007). BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med, 357, 258-65. https://doi.org/10.1056/NEJMct071828
  24. Thompson PA, Kantarjian HM, Cortes JE (2015). Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc, 90, 1440-54. https://doi.org/10.1016/j.mayocp.2015.08.010
  25. Xu L, Zhu H, Hu J, et al (2015). Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase. JOURNAL??, 9, 304-11. https://doi.org/10.1007/s11684-015-0400-4